Lobeglitazone

Lobeglitazone plus metformin was not associated with a statistically significant change in renal progression compared with the studied comparator regimens. Lobeglitazone plus metformin produced renal outcomes comparable to metformin monotherapy, sulfonylurea plus metformin, and DPP4 inhibitor plus metformin. Lobeglitazone has high affinity for PPAR-gamma because it incorporates a pyrimidine substituent into the thiazolidinedione scaffold. Lobeglitazone is a thiazolidinedione used in Korea for type 2 diabetes treatment. The study evaluated whether lobeglitazone was linked to lower renal disease progression in adults with type 2 diabetes using Korean hospital data.